News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Antares Pharma, Inc. (ANTR) Partner, TEVA Pharmaceuticals USA (TEVA), Introduces New Resources to Support Use of ANTARES' Patient-Friendly Injector for Growth Hormone Deficiency in Children


2/2/2010 10:28:12 AM

EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NYSE Amex: AIS) a leader in self injection drug delivery technology today announced that Teva USA has introduced new patient support resources for the Tjet® device and TEV-TROPIN® [somatropin (rDNA origin) for injection]. Antares licensed its novel delivery device to Teva, branded as Tjet® for delivering TEV-TROPIN® brand human growth hormone (hGH) to children who have growth failure due to inadequate secretion of normal endogenous growth hormone.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES